[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621460":3},{"organization":4,"outcomesModule":7,"designInfo":15,"detailedDescription":11,"studyPopulation":11,"armGroups":26,"interventions":40,"overallOfficials":50,"centralContacts":55,"locations":61,"responsibleParty":75,"collaborators":77,"id":80,"slug":11,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":11,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":11,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":11,"overallStatus":98,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Shanghai Longwood Biopharmaceuticals Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Proportion of subjects achieving ≥75% improvement in Eczema Area and Severity Index (EASI) from baseline at Week 16 (EASI 75)",null,"Week 16",{"measure":14,"description":11,"timeFrame":12},"Proportion of subjects achieving an Investigator's Global Assessment (IGA) score of 0 or 1 with a ≥2-point reduction from baseline at Week 16",{"allocation":16,"interventionModel":17,"interventionModelDescription":11,"primaryPurpose":18,"observationalModel":11,"timePerspective":11,"maskingInfo":19},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":20,"maskingDescription":11,"whoMasked":21},"QUADRUPLE",[22,23,24,25],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[27,32,35],{"label":28,"type":29,"description":11,"interventionNames":30},"LW402 100 mg, PO BID","EXPERIMENTAL",[31],"Drug: LW402",{"label":33,"type":29,"description":11,"interventionNames":34},"LW402 150 mg, PO BID",[31],{"label":36,"type":37,"description":11,"interventionNames":38},"LW402 placebo tablets,PO.BID","PLACEBO_COMPARATOR",[39],"Drug: Placebo",[41,46],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"DRUG","LW402","LW402 tablets",[28,33],{"type":42,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"Placebo","LW402 placebo tablets",[36],[51],{"name":52,"affiliation":53,"role":54},"Janzhong Zhang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[56],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Barbara Chen","CONTACT","+86-21-63634910","barbara@lwbiopharma.com",[62],{"facility":53,"status":11,"city":63,"state":11,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Beijing","China","CN",{"type":67,"coordinates":68},"Point",[69,70],116.39723,39.9075,{"lat":70,"lon":69},[73],{"name":74,"role":58,"phone":11,"phoneExt":11,"email":11},"Jianzhong Zhang",{"type":76,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[78],{"name":79,"class":6},"Tigermed Consulting Co., Ltd","100621460",false,"NCT07370909","Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis","A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.","Inclusion Criteria:\n\n* Subjects voluntarily provided informed consent and agreed to participate in the study.\n* Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form).\n* At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening.\n* At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:\n\n  * Total AD lesion area ≥ 10% of body surface area (BSA)\n  * Investigator's Global Assessment (IGA) score ≥ 3\n  * Eczema Area and Severity Index (EASI) score ≥ 16\n\nExclusion Criteria:\n\n* Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors.\n* Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus \\[SLE\\], inflammatory bowel disease \\[IBD\\], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).","ALL","18 Years","75 Years",{"count":90,"type":91},480,"ESTIMATED","INTERVENTIONAL",[94],"PHASE3","This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.",[97],"Moderate to Severe Atopic Dermatitis","NOT_YET_RECRUITING","2026-01-27",{"date":101,"type":102},"2026-01-29","ACTUAL",{"date":104,"type":91},"2026-01-30",{"date":106,"type":91},"2028-12-31",{"name":5,"class":6},1]